Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. (JAGX) reports that a special meeting of stockholders held on September 4, 2026 was called to order but could not proceed because there were not enough shares of voting common stock and Series Q Perpetual Preferred Stock present or represented by proxy to constitute a quorum.
No votes were taken on any of the proposals described in the definitive proxy statement filed August 3, 2026, and no business was conducted. The company states it will not adjourn or postpone this particular special meeting and it will not be reconvened, but it plans to evaluate whether to call a new special meeting in the future to consider the same, similar, or other proposals.
Jaguar Health, Inc. (JAGX) updates its at-the-market equity program, stating that the aggregate offering price of common stock it may sell under its Form S-3 ATM facility has been reduced to approximately $4.78 million pursuant to General Instruction I.B.6 of Form S-3.
The company calculates the aggregate market value of common stock held by non-affiliates at about $14.99 million, based on 5,335,075 non-affiliate shares at $2.81 per share as of July 6, 2026, and notes that approximately $214,660 of stock has been sold under the I.B.6 limits in the prior 12-month period. Ladenburg Thalmann remains the sole sales agent under the ATM Agreement, and JAGX common stock trades on Nasdaq at a last reported price of $0.7299 per share on September 2, 2026.
Jaguar Health, Inc. (symbol JAGX) has filed a prospectus covering the potential resale by two selling stockholders of up to 40,874,552 shares of voting common stock. This consists of 40,000,000 Purchase Shares that may be issued under a June 9, 2026 equity line of credit with C/M Capital Master Fund, LP and 874,552 Commitment Shares (including shares issuable from pre-funded warrants) issued as consideration for that agreement. Jaguar is not selling any shares in this offering and will receive no proceeds from stockholder resales, but may sell shares directly to C/M Capital under the Purchase Agreement for up to $40 million in aggregate gross proceeds at discounted prices tied to market VWAP, subject to conditions, a 4.99% Beneficial Ownership Limitation, and a 19.99% Nasdaq stockholder-approval cap already obtained. Shares outstanding were 4,910,402 as of July 10, 2026; if all registered shares were issued and outstanding, they would exceed 89.3% of that baseline, highlighting substantial potential dilution.
Jaguar Health, Inc. (JAGX) reported second quarter 2026 results and highlighted progress in its global development program for crofelemer targeting rare intestinal failure (IF) diseases. A key update was presentation of additional data at ESPGHAN 2026 on crofelemer as adjunctive oral therapy for pediatric IF, including ultrarare microvillus inclusion disease (MVID). The data showed a reduction of parenteral support normalized to body weight of up to 48% in a patient with MVID. Jaguar stated it expects the clinical package for a New Drug Application (NDA) for MVID to be ready by the end of 2026, with NDA submission planned for the second quarter of 2027.
Jaguar Health, Inc. (JAGX) reports markedly improved results for the six months ended June 30, 2026. Total revenue was $21.5 million, up from $5.2 million a year earlier, driven largely by a jump in license revenue to $19.1 million. Product revenue contributed $2.4 million.
Operating performance strengthened: the company recorded a net loss of $4.1 million, compared with a $21.2 million loss in the prior-year period. Operating cash flow turned positive at $3.5 million versus a $13.5 million outflow. Jaguar also reduced notes payable significantly, with total liabilities falling to $29.3 million from $57.0 million, and stockholders’ equity moving from a deficit of $18.7 million at December 31, 2025 to positive $4.9 million at June 30, 2026, aided by preferred stock and warrant transactions.
Jaguar Health, Inc. filed a notice that its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 will be filed late. The company cites delays in obtaining and compiling information, including significant and material subsequent event transactions, and states that these delays could not be resolved without unreasonable effort and expense.
Jaguar Health states that, in reliance on Rule 12b-25, it expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date. The company also cautions that previously unknown issues related to its financial statements or internal control over financial reporting could be identified and may lead to changes in anticipated results, potential delays beyond the permitted 5-day period, and possible volatility in its stock price.
Jaguar Health, Inc. filed Post-Effective Amendment No. 1 to its Form S-1 to update information on the selling stockholders and plan of distribution for an existing resale registration. The amendment relates to up to 40,874,552 shares of voting common stock previously registered for resale in connection with a June 2026 common stock purchase agreement with C/M Capital Master Fund, LP that establishes an equity line of credit.
The registered shares comprise up to 40,000,000 Purchase Shares that Jaguar may sell to C/M Capital plus up to 874,552 Commitment Shares, including shares underlying pre-funded warrants issued as consideration for entering the agreement. Jaguar is not selling securities under this prospectus and will not receive proceeds from selling stockholders’ resales, but may raise up to $40 million in gross proceeds from future sales of common stock to C/M Capital under the Purchase Agreement, subject to conditions including a $1.10 floor price, volume limits, a 4.99% beneficial ownership cap, and Nasdaq Rule 5635(d) stockholder approval.
As of July 10, 2026, Jaguar had 4,910,402 common shares outstanding; if all 40,874,552 registered shares were issued, they would represent over 89.3% of then-outstanding shares, highlighting substantial potential dilution and stock price pressure discussed in the risk factors. Proceeds from any future equity line draws are intended for working capital and general corporate purposes, including potential redemption of Series P Preferred Stock. Jaguar continues to focus on plant-derived gastrointestinal therapies, including crofelemer programs for HIV-related diarrhea, cancer therapy–related diarrhea, and rare intestinal failure conditions.
Jaguar Health, Inc. has called a special stockholder meeting for September 4, 2026 to approve several capital structure and equity proposals. Stockholders of record on July 6, 2026, holding 4,857,211 shares of Common Stock and 889.28 shares of Series Q Preferred Stock, may vote subject to a 9.99% voting cap on Series Q.
Proposal 1 seeks Nasdaq Rule 5635(d) approval to issue Common Stock upon exchange of Series Q Preferred Stock, which at an assumed $2.50 exchange price could result in up to 7,911,743 new shares, about 62.0% of pre-transaction Common Stock. Proposal 2 would reprice Investor Warrants on 60,781 shares to $1.00 and, together with 682,661 Series O dividend shares, permit issuance of up to 745,354 shares, about 13.3% of current Common Stock. Proposal 3 would amend the 2014 Stock Incentive Plan so the pool equals 14% of fully diluted shares as of September 30, 2026, versus 10,591 shares currently available (about 0.17% fully diluted). Proposal 4 would allow adjournment to seek additional proxies. The board unanimously recommends voting FOR all four proposals.
Jaguar Health, Inc. is registering the potential resale of up to 5,483,086 shares of voting common stock for existing investors, not issuing new shares in this transaction and receiving no resale proceeds. These shares may be issued under a June 9, 2026 Series P Non-Convertible Preferred Stock financing and related pre-funded warrants, including up to 4,395,605 Redemption Shares, 32,535 Commencement Shares, and up to 1,054,946 Dividend Shares based on an 8% annual dividend over three years using a $0.546 Floor Price.
The preferred financing raised $2 million through 240 Series P shares with 8% dividends payable in cash or stock subject to an Equity Condition, and is linked to a $40 million equity line of credit with C/M Capital. As of July 10, 2026, common shares outstanding were 4,910,402; if all registered shares were issued, they would represent over 52.76% of the then-outstanding common stock, creating substantial dilution and potential selling pressure. The company also discloses restrictive covenants in the preferred agreements that can limit additional financings and details anti-takeover and capital structure terms.